The latest results from the CodeBreak 100 trial evaluating AMG 510 indicate that this first-in-class KRAS inhibitor, having shown promise in non–small cell lung cancer, is modestly active in several other types of solid tumors, including colorectal cancer.

You do not currently have access to this content.